2023-508998-85-00已完成1 期
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy
Boehringer Ingelheim International GmbH, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.12 个研究点 分布在 4 个国家目标入组 48 人开始时间: 2024年8月5日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 试验地点
- 12
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (12)
Loading locations...
相似试验
招募中
不适用
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapyjRCT2031240308Nippon Boehringer Ingelheim Co., Ltd10
招募中
1 期
This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)2024-511503-41-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.112
招募中
不适用
A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancersjRCT2041230084Nippon Boehringer Ingelheim Co., Ltd.120
招募中
不适用
A study to test different doses of BI 764532 combined with ezabenlimab in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3.jRCT2031220716Boehringer Ingelheim4
招募中
不适用
A study to test whether different doses of BI 690517 alone or in combination with empagliflozin improve kidney function in people with chronic kidney diseasechronic kidney diseasejRCT2031210597Boehringer Ingelheim552